The following is a summary of "Controversial Role Of Cd151 In Different Solid Tumors: Promoter Or Suppressor?,” published in ...

Compass Therapeutics, Inc.’s CMPX share price has surged by 17.89%, which has investors questioning if this is right time to sell.

Compass Therapeutics, Inc.’s CMPX share price has dipped by 15.53%, which has investors questioning if this is right time to buy.

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one ...

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...

Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.

Wedbush reiterated their outperform rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a report ...

Adcendo, a biotech company pioneering the development of first- and potential best-in-class antibody-drug conjugates (ADCs) for cancers with a high unmet medical need, today announced two important ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...

Intech Investment Management LLC increased its holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report) by 218.7% ...

Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET. Company Participants. Douglas Onsi - President ...

Hyundai ADM Bio (KOSDAQ symbol 187660) announced on the 24th that its first-in-class pseudo-resistance-targeting agent, ...